boilermaker55
Gold Member
- Aug 12, 2011
- 6,795
- 755
Drugmakers ring in 2016 with hefty price hikes
"Drugmakers including Pfizer (PFE) and Allergan (AGN) have boosted prices on many brand-name medications since last month. The price hikes, ranging from 1.3 percent to 42.3 percent, reflect the list prices, which don't represent the discounts and rebates negotiated by insurers and health care providers."
"Since Jan. 1, Pfizer has boosted the list prices of dozens of drugs, with the average increase set at 10.6 percent, according to a new report from Deutsche Bank. Even though it's common practice for drugmakers to lift prices at the start of each year, the pharmaceutical industry is increasingly under the spotlight for what some lawmakers and patients allege amounts to price gouging."
"
Pfizer Inc. reported second-quarter earnings that beat analysts’ estimates and raised its full-year profit forecast as sales of a new cancer drug climbed.
Adjusted earnings of 56 cents a share topped the average projection of 52 cents, according to data compiled by Bloomberg. First-quarter sales of $11.9 billion compared with analysts’ projection of $11.4 billion.
The drug Ibrance, approved in February by U.S. regulators for use in advanced breast cancer, generated $140 million in sales, compared with the $95.3 million projected by analysts. Ibrance will be a $3.39 billion drug by 2018, according to analysts’ estimates. Total oncology sales, including drugs such as Sutent, Inlyta and Xalkori, rose 25 percent from a year earlier."
Pfizer Profit Beats Estimates as Cancer Drug Sales Increase
"Drugmakers including Pfizer (PFE) and Allergan (AGN) have boosted prices on many brand-name medications since last month. The price hikes, ranging from 1.3 percent to 42.3 percent, reflect the list prices, which don't represent the discounts and rebates negotiated by insurers and health care providers."
"Since Jan. 1, Pfizer has boosted the list prices of dozens of drugs, with the average increase set at 10.6 percent, according to a new report from Deutsche Bank. Even though it's common practice for drugmakers to lift prices at the start of each year, the pharmaceutical industry is increasingly under the spotlight for what some lawmakers and patients allege amounts to price gouging."
"
Pfizer Inc. reported second-quarter earnings that beat analysts’ estimates and raised its full-year profit forecast as sales of a new cancer drug climbed.
Adjusted earnings of 56 cents a share topped the average projection of 52 cents, according to data compiled by Bloomberg. First-quarter sales of $11.9 billion compared with analysts’ projection of $11.4 billion.
The drug Ibrance, approved in February by U.S. regulators for use in advanced breast cancer, generated $140 million in sales, compared with the $95.3 million projected by analysts. Ibrance will be a $3.39 billion drug by 2018, according to analysts’ estimates. Total oncology sales, including drugs such as Sutent, Inlyta and Xalkori, rose 25 percent from a year earlier."
Pfizer Profit Beats Estimates as Cancer Drug Sales Increase